ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW
Estrella Immunopharma, Inc.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.38−0.05 (-11.65%)
Close on Oct 19, 2026
- Market cap
- $16.17M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5M
Shares held, 13F filers
Institutional holders
15
2 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Eureka Therapeutics, Inc. | 25,277,831 | 71.80% | 13D (active) | Sep 29, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ESLA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 3,975,220 | – | $4.13M | −123,780 | 0.05% |
| Vanguard Capital Management LLC | 416,852 | – | $433.53K | +34,383 | 0.00% |
| Geode Capital Management, LLC | 141,321 | – | $146.97K | −16,164 | 0.00% |
| Vanguard Fiduciary Trust Co | 64,921 | – | $67.52K | – | 0.00% |
| BlackRock, Inc. | 52,033 | – | $54.11K | +12,143 | 0.00% |
| State Street Corp | 43,252 | – | $44.98K | – | 0.00% |
| Renaissance Technologies LLC | 39,100 | – | $40.66K | −23,695 | 0.00% |
| Northern Trust Corp | 34,861 | – | $36.26K | +15,237 | 0.00% |
| US Bancorp \de\ | 20,000 | – | $20.80K | +3,096 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,308 | – | $3.44K | −1,551 | 0.00% |
| UBS Group AG | 1,721 | – | $1.79K | −13,358 | 0.00% |
| Toronto Dominion Bank | 1,089 | – | $1.13K | – | 0.00% |
| Wolverine Asset Management LLC | 468 | – | $487 | – | 0.00% |
| Barclays PLC | 126 | – | $131 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | – | $2 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 15 | 5M | 2 / 4 | 5 / 3 | 0M | 0M |
| Q1 2026 | 16 | 5M | 8 / 3 | 2 / 6 | 5M | 0M |
| Q4 2025 | 15 | 1M | 6 / 8 | 1 / 2 | 0M | 0M |
| Q3 2025 | 13 | 1M | 3 / 1 | 6 / 1 | 0M | 0M |
| Q2 2025 | 11 | 1M | 1 / 5 | 2 / 1 | 0M | 0M |
| Q1 2025 | 11 | 1M | 1 / 4 | 3 / 1 | 0M | 0M |
| Q4 2024 | 11 | 0M | 2 / 3 | 2 / 1 | 0M | 0M |
| Q3 2024 | 10 | 0M | 4 / 3 | 1 / 0 | 0M | 0M |
| Q2 2024 | 7 | 0M | 3 / 1 | 0 / 2 | 0M | 0M |
| Q1 2024 | 6 | 0M | 0 / 3 | 0 / 1 | 0M | 0M |
| Q4 2023 | 7 | 0M | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ESLA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 268,605 | – | $279.35K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 148,247 | – | $154.18K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 99,247 | – | $108.18K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 49,660 | – | $51.65K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 27,548 | – | $30.03K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 16,762 | – | $18.27K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 2,373 | – | $2.47K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,582 | – | $1.72K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Cheng Liu | CEO, Director | 397,437 | Aug 26, 2026 |
| Jiandong Xu | Chief Financial Officer | 382,188 | Aug 25, 2026 |
| Dengyao Jia | Director | – | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cheng Liu CEO, Director | Aug 25, 2026 | Option exercise | +100,000 | $0.82 | $82.00K | 397,437 |
| Jiandong Xu Chief Financial Officer | Aug 18, 2026 | Option exercise | +100,000 | $0.82 | $82.00K | 365,488 |
| Jiandong Xu Chief Financial Officer | Oct 7, 2025 | Buy | +1,000 | $1.33 | $1.33K | 265,488 |
| Jiandong Xu Chief Financial Officer | Sep 22, 2025 | Buy | +1,000 | $1.16 | $1.16K | 16,700 |
| Jiandong Xu Chief Financial Officer | Sep 11, 2025 | Buy | +100 | $1.04 | $104 | 264,588 |
| Jeffrey A. Altman 10% owner | Sep 29, 2023 | Other | −255,000 | $10.86 | $2.77M | 0 |
| Jianwei Li Co-Chief Executive Officer, Director, 10% owner | Mar 4, 2022 | Buy | +141,970 | $314700.00 | $44.68B | 1,253,730 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.